Tislelizumab for untreated Hodgkin lymphoma when chemo isn’t suitable
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial tests tislelizumab (an immune therapy) in people with newly diagnosed classical Hodgkin lymphoma who cannot safely get standard chemotherapy. It aims to see how well the treatment works and whether it is safe for older adults and others with health limits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of classical Hodgkin lymphoma that was newly found
- You have never had treatment for Hodgkin lymphoma before
- You are age 65 or older and standard chemotherapy isn’t suitable for you due to other health problems
- Your lymphoma can be measured on scans (PET-avid lymph nodes plus a measurable node lesion)
- You are well enough to do daily activities (ECOG performance status 0 to 2)
- Your blood counts and organs (kidneys, liver, etc.) are strong enough for treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called tislelizumab (an immunotherapy that helps your immune system fight cancer) added to standard chemotherapy for older adults with newly diagnosed Hodgkin lymphoma. The goal is to see if adding this drug improves outcomes without too many side effects.
This trial studies a customized immune-based treatment approach for people with early-stage “unfavorable” classical Hodgkin lymphoma who have not had prior treatment. It may help by targeting your lymphoma using an individualized plan based on your case.
This trial tests a new combination of two immunotherapy drugs (IMM01 and tislelizumab) compared with standard chemotherapy for people with classical Hodgkin lymphoma that has not responded to PD-1/PD-L1 inhibitors. The goal is to see if this new approach can help when other treatments have failed.
This trial tests a combination of the immunotherapy drug tislelizumab with two chemotherapy drugs (gemcitabine and peraspartase) for people with newly diagnosed stage I or II NK/T-cell lymphoma. The goal is to see if this combination works well and is safe.
This trial tests a drug called tislelizumab (a type of immunotherapy) for people with advanced solid tumors that have stopped responding to standard treatments. The drug may help your immune system fight the cancer, but only if your tumor shows a specific genetic marker.
This trial tests a combination of five drugs for people newly diagnosed with a rare type of lymphoma called angioimmunoblastic T-cell lymphoma (AITL). The goal is to see if this treatment helps control the cancer.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.